Kline et al. first described inactivating germline mutations of MUTYH in two pediatric patients with high-grade gliomas (one glioblastoma with Histone H3 K27M–mutant protein expression and one medulloblastoma) in 2016 [9]. This evidence concerns the gene MUTYH and central nervous system cancer.